Página inicial > Blogs > Breast Cancer Recurrence: The Emerging Role of ctDNA

Breast Cancer Recurrence: The Emerging Role of ctDNA

Detecting Molecular Clues That May Signal Cancer's Return

Breast cancer recurrence remains a significant challenge in cancer care. Even after successful treatment, small amounts of cancer may persist without being detectable through conventional imaging or clinical assessment. Identifying these molecular changes earlier is an important focus of ongoing research in precision oncology.

Circulating tumor DNA (ctDNA) is gaining attention for its potential to detect molecular residual disease (MRD), assess recurrence risk, and provide insights into tumor evolution. At DNA GTx, advances in genomic testing and liquid biopsy reflect the growing role of molecular analysis in supporting a deeper understanding of cancer biology.

Understanding ctDNA in Breast Cancer

Cell-free DNA (cfDNA) consists of short DNA fragments released into the bloodstream by cells throughout the body. A proportion of this DNA may originate from tumor cells and is known as circulating tumor DNA (ctDNA).

Through liquid biopsy, ctDNA can be analyzed using a blood sample, offering a minimally invasive approach to investigating tumor-associated genetic alterations. In breast cancer, researchers are exploring its potential to identify residual disease after treatment, monitor molecular changes over time, and detect alterations associated with treatment resistance. However, the sensitivity of ctDNA analysis can vary depending on tumor biology, disease burden, and assay design. [1,2]

DNA GTx’s focus on genomic testing aligns with this evolving field, where sensitive molecular analysis can help reveal genetic information that may complement conventional clinical assessment.

What Can ctDNA Analysis Reveal?

Depending on the assay design and clinical context, ctDNA analysis may provide several types of molecular insight:

Molecular residual disease (MRD): Detecting tumor-associated DNA that may remain after treatment.
Recurrence risk: Identifying molecular signals associated with an increased likelihood of relapse.
Tumor evolution: Tracking genetic changes that emerge as cancer develops or responds to treatment.
Potential treatment resistance: Identifying alterations that may contribute to reduced sensitivity to certain therapies.

These applications are related but distinct. Their reliability and clinical relevance depend on factors such as assay sensitivity, tumor biology, disease stage, and the amount of ctDNA present in the blood. [2]

Understanding Molecular Residual Disease

MRD refers to cancer-related disease that persists after treatment but remains below the detection limits of conventional methods. Research in early-stage breast cancer has shown that ctDNA detection during follow-up can precede clinically apparent recurrence in some patients. In a prospective study, ctDNA detection anticipated clinical relapse by a median of 10.7 months, although the findings do not establish that acting on this signal improves patient outcomes. [1]

Different testing strategies are used to investigate ctDNA. Tumor-informed assays are designed using genetic alterations identified in an individual patient’s tumor, while tumor-naïve assays assess selected biomarkers without requiring prior tumor sequencing. Each approach has distinct strengths and limitations, and performance can vary according to the assay and clinical setting.

Although ctDNA detection may provide an early molecular signal of recurrence risk, important limitations remain. Some tumors release very little DNA into the bloodstream, meaning that a negative result cannot reliably exclude residual disease. A positive result also does not, by itself, establish clinically confirmed recurrence. [1,2]

For DNA GTx, this field highlights the importance of robust genomic analysis, appropriate assay selection, and careful interpretation of molecular findings within their intended clinical context.

From Prognostic Information to Clinical Utility

One of the most important questions in ctDNA research is how molecular findings can be translated into improved patient outcomes.

Detecting ctDNA may help identify patients at increased risk of recurrence, but evidence is still developing on whether acting on these findings, such as changing treatment or initiating intervention earlier improves outcomes. The distinction between prognostic value and clinical utility is therefore essential.

The European Society for Medical Oncology (ESMO) recognizes the clinical validity of MRD detection in anticipating relapse, while noting that evidence is currently insufficient to recommend MRD-guided treatment decisions in routine practice. [2] At present, ctDNA testing should complement established clinical assessment and follow-up rather than replace standard surveillance.

DNA GTx: Connecting Liquid Biopsy and Genomic Insight

At DNA GTx, we recognize the growing importance of genomic testing in understanding cancer at the molecular level. Liquid biopsy and tissue-based genomic profiling offer complementary approaches to investigating tumor-associated alterations, each with a role determined by the test’s intended use and clinical context.

As ctDNA technologies continue to develop, advances in analytical sensitivity, variant detection, and genomic interpretation will be important for generating reliable molecular information. These developments also reinforce the need to distinguish between tests designed to characterize tumor alterations and those specifically developed and validated for MRD assessment or recurrence monitoring.

By keeping pace with advances in genomic science, DNA GTx is committed to supporting a more informed understanding of molecular testing and its evolving place in precision oncology.

The Future of ctDNA in Breast Cancer Recurrence

ctDNA research is expanding the possibilities for studying breast cancer recurrence beyond conventional clinical measures. Its potential to reveal molecular changes before they become clinically apparent makes it an important area of investigation, particularly for MRD assessment and recurrence-risk stratification. [1,2]

However, further evidence is needed to establish how ctDNA results should guide surveillance and treatment decisions in routine practice. Continued research, analytical validation, and clinical evaluation will be essential to defining where these approaches can provide the greatest benefit.

Na DNA GTx, we remain committed to advancing genomic science and supporting the development of molecular testing approaches that connect technological innovation with clinically meaningful insight.

DNA GTx — Avançando a Genômica para a Saúde de Precisão

Clinical note: The use of ctDNA for breast cancer recurrence monitoring remains an evolving area of research. Results should be interpreted in the appropriate clinical context. ctDNA testing should not replace standard follow-up or independently guide treatment decisions outside established guidance or appropriate clinical research.

📚Referências

Gonzalez-Billalabeitia, Enrique, Vincenza Conteduca, Daniel Wetterskog, Anuradha Jayaram, and Gerhardt Attard. “Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.” Prostate cancer and prostatic diseases 22, no. 2 (2019): 195-205.
Garcia-Murillas, Isaac, Neha Chopra, Iñaki Comino-Méndez, Matthew Beaney, Holly Tovey, Rosalind J. Cutts, Claire Swift et al. “Assessment of molecular relapse detection in early-stage breast cancer.” JAMA oncology 5, no. 10 (2019): 1473-1478.

Redes